Symbols / CYTO
CYTO Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-04-15 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | $0.00 |
| Price | $0.30 | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- 5 metastatic breast cancer patients alive 63 months after leronlimab - Stock Titan Fri, 20 Feb 2026 13
- Cytophage Announces Operational Restructuring (2026-02-19) - Seeking Alpha hu, 19 Feb 2026 13
- CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire hu, 13 Nov 2025 08
- CytoDyn (OTCQB: CYDY) obtains $30M Yorkville equity facility over 36 months - Stock Titan Mon, 03 Nov 2025 08
- Cytokinetics Announces FDA Approval of MYQORZOâ„¢ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms - Cytokinetics Fri, 19 Dec 2025 08
- CytoSorbents (NASDAQ: CTSO) to present at Jefferies Healthcare Conference in London - Stock Titan Mon, 17 Nov 2025 08
- Cytophage Technologies Ltd. Completes Reverse Takeover Transaction of Cuspis Capital III Ltd. - TheNewswire Sun, 09 Jun 2024 11
- What's Going On With Altamira Therapeutics Stock? - Sahm hu, 23 May 2024 07
- CytoDyn (OTCQB: CYDY) inks class action resolution deal, pending court approval - Stock Titan Mon, 01 Dec 2025 08
- Cancer cell therapy company hits back at claims about its first human trial - Stock Titan Wed, 28 Jan 2026 08
- CytoMed Therapeutics (NASDAQ: GDTC) Chairman Now Owns 21.95%, 2,388,246 Shares - Stock Titan Wed, 22 Oct 2025 07
- CytoDyn (OTCQB: CYDY) reports PD-L1 upregulation in 76% of mTNBC patients on leronlimab - Stock Titan Mon, 08 Dec 2025 08
- Biotech seeks investor views on share-based access to cell therapy - Stock Titan ue, 13 Jan 2026 08
- Royal Caribbean (NYSE: RCL) launches unsecured notes sale to finance Celebrity Xcel - Stock Titan ue, 18 Nov 2025 08
- Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer - Stock Titan hu, 15 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CYTO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|